PMID- 34952122
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 300
DP  - 2022 Mar 1
TI  - Long-term outcomes of repeated ketamine infusions in patients with unipolar and 
      bipolar depression: A naturalistic follow-up study.
PG  - 172-178
LID - S0165-0327(21)01383-5 [pii]
LID - 10.1016/j.jad.2021.12.084 [doi]
AB  - OBJECTIVE: Ketamine was proven to have short-term antidepressant effects. There 
      is a paucity of studies focused on the long-term outcomes of repeated infusions 
      of ketamine. This study aimed to examine the long-term outcomes of repeated 
      ketamine infusions in patients with unipolar and bipolar depression METHODS: One 
      hundred and eight patients with unipolar and bipolar depression completed the 
      repeated treatment phase (administered ketamine three times weekly over a 12-day) 
      and entered a 9-month naturalistic follow-up phase. Assessments were obtained at 
      week 2, month 6, and month 9 after the repeated treatment phase. The Patient 
      Health Questionnaire-9 (PHQ-9) Scale and the Global Assessment of Functioning 
      (GAF) Scale were used to assess depressive symptoms and global functional status, 
      respectively. RESULTS: Seventy-one (65.7%) of patients completed the 9-month 
      follow-up. On month 9, the response and remission rate were 80.3% and 78.9%, 
      respectively. Among 56 patients who achieved response after the repeated 
      treatment phase, 26 (46.4%) of patients sustained response during 9-month 
      follow-up and their GAF score remained over 70. Sixteen patients relapsed during 
      the 9-month follow-up and 14 (85.7%) of the relapse occurred during the first 
      2-week follow-up. LIMITATION: The major limitation of this study is the 
      open-label design. CONCLUSIONS: This small sample study suggested that patients 
      with unipolar and bipolar depression who response to repeated treatment with 
      continued oral antidepressant may be a viable treatment option, and their global 
      functional status improved with a follow-up. Relapse of depression tended to 
      occur during the 2 weeks follow-up.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - Li, Weicheng
AU  - Li W
AD  - The First School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China; The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou 
      Huiai Hospital), Guangzhou, China; Guangdong Engineering Technology Research 
      Center for Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Zhou, Yanling
AU  - Zhou Y
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Liu, Weijian
AU  - Liu W
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China; Institute of Mental 
      Health, National Clinical Research Center for Mental Disorders, Key Laboratory of 
      Mental Health and Peking University Sixth Hospital, Peking University, Beijing, 
      China.
FAU - Wang, Chengyu
AU  - Wang C
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Lan, Xiaofeng
AU  - Lan X
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Zhang, Zhipei
AU  - Zhang Z
AD  - The First School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China; The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou 
      Huiai Hospital), Guangzhou, China; Guangdong Engineering Technology Research 
      Center for Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Ye, Yanxiang
AU  - Ye Y
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Liu, Haiyan
AU  - Liu H
AD  - The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai 
      Hospital), Guangzhou, China; Guangdong Engineering Technology Research Center for 
      Translational Medicine of Metal Disorders, Guangzhou, China.
FAU - Wu, Kai
AU  - Wu K
AD  - Department of Biomedical Engineering, School of Material Science and Engineering, 
      South China University of Technology, China.
FAU - McIntyre, Roger S
AU  - McIntyre RS
AD  - Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Mood 
      Disorders Psychopharmacology Unit, Poul Hansen Depression Centre, University 
      Health Network, Toronto, ON, Canada; Department of Psychiatry, University of 
      Toronto, Toronto, ON, Canada; Institute of Medical Science, University of 
      Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, 
      ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, 
      Canada.
FAU - Ning, Yuping
AU  - Ning Y
AD  - The First School of Clinical Medicine, Southern Medical University, Guangzhou, 
      China; The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou 
      Huiai Hospital), Guangzhou, China; Guangdong Engineering Technology Research 
      Center for Translational Medicine of Metal Disorders, Guangzhou, China. 
      Electronic address: ningjeny@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211222
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 690G0D6V8H (Ketamine)
SB  - IM
MH  - *Bipolar Disorder/chemically induced/drug therapy
MH  - *Depressive Disorder, Treatment-Resistant/drug therapy
MH  - Follow-Up Studies
MH  - Humans
MH  - Infusions, Intravenous
MH  - *Ketamine
OTO - NOTNLM
OT  - Ketamine
OT  - Long-term outcomes
OT  - Repeated infusions
EDAT- 2021/12/25 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/12/24 20:10
PHST- 2021/05/07 00:00 [received]
PHST- 2021/10/14 00:00 [revised]
PHST- 2021/12/19 00:00 [accepted]
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2021/12/24 20:10 [entrez]
AID - S0165-0327(21)01383-5 [pii]
AID - 10.1016/j.jad.2021.12.084 [doi]
PST - ppublish
SO  - J Affect Disord. 2022 Mar 1;300:172-178. doi: 10.1016/j.jad.2021.12.084. Epub 
      2021 Dec 22.